We are live on ! Find out more
IGMS

IGM Biosciences
IGMS

Delisted

IGMS was delisted on the 13th of August, 2025.

Back to rankings

93 hedge funds and large institutions have $487M invested in IGM Biosciences in 2022 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 33 increasing their positions, 19 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

90% more call options, than puts

Call options by funds: $15M | Put options by funds: $7.91M

74% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 19

29% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 21

7% more funds holding

Funds holding: 87 → 93 (+6)

2.34% more ownership

Funds ownership: 67.77% → 70.11% (+2.3%)

5% less capital invested

Capital invested by funds: $514M → $487M (-$26.9M)

Holders
93
Holders Change
+6
Holders Change %
+6.9%
% of All Funds
1.47%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
27
Increased
33
Reduced
19
Closed
21
Calls
$15M
Puts
$7.91M
Net Calls
+$7.11M
Net Calls Change
+$6.92M

Top Buyers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
+$9.31M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$7.73M
3
EC
EcoR1 Capital
California
+$5.56M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$4.72M
5
UBS AM
UBS AM
Illinois
+$3.72M

Top Sellers

Rank Fund Capital Flow
1
PAMS
Pictet Asset Management (Switzerland)
Switzerland
-$27.4M
2
State Street
State Street
Massachusetts
-$10.4M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$2.33M
4
EGP
Entrust Global Partners
New York
-$1.94M
5
CAM
Cormorant Asset Management
Massachusetts
-$1.82M
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
76
UBS Group
Switzerland
$29K -$960K -51,556 -98%
ACM
77
Aquatic Capital Management
Illinois
$19K +$13K +700 New
CG
78
Cutler Group
California
$18K +$13K +700 New
AIP
79
Ameritas Investment Partners
Nebraska
$17K – – –
Canada Life
80
Canada Life
Manitoba, Canada
$16K – – –
LC
81
Lindbrook Capital
California
$15K +$10.1K +545 New
S
82
SignatureFD
Georgia
$13K +$9.03K +485 New
QT
83
Quantbot Technologies
New York
$12K -$1.17K -63 -12%
EWM
84
Endurance Wealth Management
Rhode Island
$8K – – –
Fidelity Investments
85
Fidelity Investments
Massachusetts
$7K +$4.77K +256 New
QCG
86
Quadrant Capital Group
Ohio
$5K +$3.22K +173 New
Osaic Holdings
87
Osaic Holdings
Arizona
$5K +$3.39K +182 +1,011%
Wells Fargo
88
Wells Fargo
California
$3K -$70.7K -3,795 -97%
PFS
89
Prospera Financial Services
Texas
$3K +$1.82K +98 New
Daiwa Securities Group
90
Daiwa Securities Group
Japan
$2K – – –
ED
91
Exane Derivatives
France
$1.28K – – –
Macquarie Group
92
Macquarie Group
Australia
$15 – – –
PAMS
93
Pictet Asset Management (Switzerland)
Switzerland
– -$27.4M -934,965 Closed
PCH
94
Polar Capital Holdings
United Kingdom
– -$3.12K -106,436 Closed
EGP
95
Entrust Global Partners
New York
– -$1.94M -66,172 Closed
Rafferty Asset Management
96
Rafferty Asset Management
New York
– -$1.64M -56,057 Closed
Walleye Capital
97
Walleye Capital
New York
– -$1.03M -35,127 Closed
Norges Bank
98
Norges Bank
Norway
– -$1.01M -34,463 Closed
Qube Research & Technologies (QRT)
99
Qube Research & Technologies (QRT)
United Kingdom
– -$944K -32,202 Closed
Russell Investments Group
100
Russell Investments Group
United Kingdom
– -$742K -25,345 Closed
1 2 3
4
5

IGMS Hedge Fund Activity: Q1 2022 in Review

93 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in IGM Biosciences (IGMS) for Q1 2022, worth a combined $487M — down 5.2% from $514M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new IGMS positions and 21 closed out — a net gain of 6 holders — while 33 added to existing stakes and 19 trimmed.

The largest buyer was Artal Group, adding an estimated $9.31M. The largest seller was Pictet Asset Management (Switzerland), exiting entirely with an estimated $27.4M sold.

  • 93 institutional investors held IGM Biosciences (IGMS) as of Q1 2022, up from 87 in Q4 2021.
  • Funds reported $487M of IGM Biosciences stock for Q1 2022, down 5.2% quarter-over-quarter.
  • 27 funds opened new IGM Biosciences positions in Q1 2022 and 21 closed out, a net change of +6 holders.
  • The largest IGM Biosciences buyer in Q1 2022 was Artal Group, an estimated $9.31M added.
  • The largest IGM Biosciences seller in Q1 2022 was Pictet Asset Management (Switzerland), an estimated $27.4M sold.

Based on aggregated 13F filings for Q1 2022.